Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Aslan Pharma Plans $40 Million Taiwan IPO in May

publication date: Apr 12, 2017
Aslan Pharma, a Singapore company developing novel oncology therapies, told Bloomberg News that it expects to raise $40 million in a Taiwan IPO planned for May. The company will float about 10% of its shares, implying a $400 million valuation. So far, Aslan has raised over $100 in venture capital, a number that includes a $23 million funding last year in a pre-IPO round. In February, Aslan reported positive results from a Phase II trial of its lead drug, varlitinib, as a second-line therapy for patients with HER-positive breast cancer. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital